Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
GLP-1 support supplements address both challenges simultaneously
We also plan ahead for comfort and adherence by addressing common GLP-1 side effect risks early and adjusting pacing when needed
Gradual weight loss over rapid loss: A slower, more controlled caloric deficit preserves more structural tissue
Lauren A Jones, Daniel I Brierley, GLP-1 and the Neurobiology of Eating Control: Recent Advances, Endocrinology , Volume 166, Issue 2, February 2025, bqae167, Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, Adrian CL
The intensive treatment of the multiple risk factors reduces the development/progression of renal disease18 which is why guidelines insist on comprehensive management of the patient with diabetes (glycemic control and control of cardiovascular risk factors, use of renin-angiotensin system inhibitors, as well as lifestyle changes, including smoking cessation or weight loss in overweight/obese individuals, among others).19 However, the residual renal risk remains very high in optimally treated patients.20 More recently, iSGLT2 has been shown to reduce the risk of cardiovascular and renal events, but still, the residual risk of renal disease progression remains high.21,22 Nevertheless, although the rate of diabetes-related complications (such as myocardial infarction, stroke, lower limb amputations or mortality) have decreased significantly in recent decades, this is not the same for CKD patients requiring renal replacement therapy attributed to diabetic kidney disease (DKD).23 Therefore new treatments are needed that improve glycemic control independently of GFR, with a low risk of hypoglycemia and able to reduce cardiovascular and renal risk in this population
US$ 28.20
US$ 21.28
US$ 28.29
US$ 23.57
